GleamWall
中文EN

IGC IGC Pharma, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1326205 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.9%
TTM net income YoY-25.8%
TTM EPS YoY7.4%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—

Margins

Gross margin16.5%
Operating margin-802.7%
Net margin-643.7%
FCF margin-415.2%
EBITDA margin-786.5%

Returns

ROE-111.1%
ROA-83.3%
ROIC (approx.)-120.6%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets33.2%
Debt / equity0.00x
Current ratio0.42x
Interest coverage-1,685.67x

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312026Q22025-09-302026Q12025-06-302025Q42025-03-312025Q32024-12-31
Income statement
Revenue$328,000$265,000$317,000$350,000$191,000$328,000$330,000$257,000
Cost of revenue$267,000$217,000$262,000$306,000$92,000$174,000$176,000$153,000
Gross profit$61,000$48,000$55,000$44,000$99,000$154,000$154,000$104,000
R&D expense$1.01M$1.39M$1.27M$1.48M$1.59M$851,000$997,000$852,000
SG&A expense$979,000$1.44M$1.24M$1.50M$1.41M$1.21M$570,000$1.13M
Operating income-$1.93M-$2.78M-$2.46M-$2.94M-$2.90M-$1.91M-$1.41M-$1.88M
Interest expense$1,000$2,000$1,000$2,000$1,000$1,000$2,000$2,000
Pretax income-$2.05M-$2.94M-$2.40M-$726,000-$1.82M-$1.60M-$1.20M-$1.83M
Income tax$0$0$0$0$0$0$0$0
Net income-$2.05M-$2.94M-$2.40M-$726,000-$1.82M-$1.60M-$1.20M-$1.83M
EBITDA-$1.89M-$2.74M-$2.40M-$2.88M-$2.79M-$1.78M-$1.26M-$1.73M
EPS (basic)-0.02-0.03-0.02—-0.02-0.02-0.02-0.02
EPS (diluted)-0.02-0.03-0.02—-0.02-0.02-0.02-0.02
Weighted avg. shares (diluted)109.49M100.33M98.16M—90.46M83.03M79.66M77.63M
Balance sheet
Cash & equivalents$377,000$331,000$207,000$900,000$1.10M$454,000$405,000$470,000
Short-term investments$36,000$23,000$28,000$38,000$25,000—$0—
Receivables$68,000$56,000$37,000$12,000$41,000$87,000$34,000$49,000
Inventory$643,000$640,000$638,000$640,000$658,000$1.35M$1.36M$1.43M
Current assets$1.31M$1.26M$1.15M$1.79M$2.00M$2.15M$2.90M$3.05M
PP&E, net$2.03M$2.07M$2.10M$2.14M$2.17M$3.10M$3.22M$3.35M
Intangibles$5.74M$5.51M$5.27M$5.10M$4.88M$2.00M$1.85M$1.87M
Total assets$9.73M$9.50M$9.19M$9.71M$9.74M$7.94M$8.75M$9.08M
Current liabilities$3.10M$3.21M$2.87M$2.16M$1.51M$1.73M$2.26M$2.66M
Short-term debt———$3,000$4,000$3,000$3,000$3,000
Long-term debt———$131,000$132,000$133,000$134,000$134,000
Total debt———$134,000$136,000$136,000$137,000$137,000
Total liabilities$3.23M$3.36M$3.06M$2.29M$1.65M$1.86M$2.42M$2.82M
Shareholders' equity$6.50M$6.13M$6.12M$7.42M$8.09M$6.08M$6.33M$6.26M
Net debt———-$766,000-$969,000-$318,000-$268,000-$333,000
Shares outstanding114.35M102.42M98.80M95.04M91.96M84.14M80.88M78.20M
Cash flow statement
Operating cash flow-$1.42M-$1.35M-$1.22M-$1.22M-$2.09M-$1.41M-$730,000-$1.32M
Capital expenditure$0$5,000$1,000$12,000$29,000$8,000$18,000$27,000
Free cash flow-$1.42M-$1.35M-$1.22M-$1.24M-$2.12M-$1.42M-$748,000-$1.34M
Investing cash flow-$193,000-$254,000-$170,000-$228,000-$374,000$580,000-$142,000-$104,000
Financing cash flow$1.67M$1.73M$710,000$1.26M$3.11M$851,000$805,000$345,000
Depreciation & amortization$41,000$41,000$58,000$64,000$106,000$127,000$154,000$144,000
Stock-based compensation-$200,000$200,000$4.00M-$100,000$730,000$4.70M$455,000$381,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.